Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

SMARCA4 is a haploinsufficient B cell lymphoma tumor suppressor that fine-tunes centrocyte cell fate decisions

Cancer Cell(2024)10.1016/j.ccell.2024.02.011Source: DataRank Database

SMARCA4 is a haploinsufficient B cell lymphoma tumor suppressor that fine-tunes centrocyte cell fate decisions is a research paper published in Cancer Cell (2024). On theSindex it has a DataRank of 0. It has been cited 31 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access31 citations

Download PDF

Cite:

Linked data & code

geo gen cellosaurus uniprot

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (8 grants)Impact (FWCI 5.01)OA: hybridTopics (34)IDs (PubMed, PMC, OpenAlex)Annotations (4)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (29)

Priya Lakra,Panhong Gou ORCID,Haopeng Yang ORCID,Cem Meydan ORCID,Matthew Teater

Live enrichment

PubMed:38458188 PMC:PMC11003852 OpenAlex:https://openalex.org/W4392546260

CPRIT

Grant: RP220208

NIH

Grant: R01CA266279

NIH

Grant: CA16672

NCI NIH HHS

Grant: P30 CA016672

NCI NIH HHS

Grant: P50 CA126752

NCI NIH HHS

Grant: K99 CA246080

National Cancer Institute

Leukemia and Lymphoma Society

FWCI

5.01

Citation Percentile

1.0%

Citation Trend

2024

2025

2026

hybridLicense: cc-by-nc-nd

journalhttps://doi.org/10.1016/j.ccell.2024.02.011

publisherhttps://doi.org/10.1016/j.ccell.2024.02.011

publisherhttps://api.elsevier.com/content/article/PII:S1535610824000552?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1535610824000552?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/38458188

Fields of Study

Chromatin Remodeling and CancerGenomics and Chromatin DynamicsCancer Mechanisms and Therapy

MeSH Terms

AnimalsChromatinDNA HelicasesHumansHyperplasiaNuclear ProteinsTranscription FactorsLymphoma, B-CellMiceHaploinsufficiency

Keywords

HaploinsufficiencySMARCA4BCL6Cancer researchLymphomaBiologyGerminal centerEZH2Transcription factorChromatinChromatin remodelingGeneticsImmunologyB cellGenePhenotypeTranscriptionB-cellEpigeneticsSwi/snfBaf

Sustainable Development Goals

SDG 0: Good health and well-being

SMARCA4 is a haploinsufficient B cell lymphoma tumor suppressor that fine-tunes centrocyte cell fate decisions

FAIR Checklist

Authors (29)

Funding (8 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)